Home » Topics » Disease categories and therapies » Dental

Dental
RSS

Acacia Pharma initiates phase II study of locally administered xerostomia drug

July 25, 2011

PMX-30063 shows activity against oral mucositis in animal study

May 24, 2011

Septodont acquires local anesthesia reversal agent OraVerse from Novalar

March 21, 2011

Acacia Pharma completes phase I APD-515 trial for xerostomia in advanced cancer

Feb. 16, 2011

Oragenics plans second phase I trial of SMaRT replacement therapy

Feb. 2, 2011

Strativa launches Oravig in U.S. for oropharyngeal candidiasis

Aug. 25, 2010

Access Pharma and BioScrip sign MuGard distribution agreement

July 22, 2010

Sanofi-aventis and Novalar submit OraVerse MAA in five European countries

July 16, 2010

FDA approves BioAlliance's Oravig for oropharyngeal candidiasis

April 20, 2010

BioDelivery Sciences presents update on BEMA Buprenorphine

March 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...